At the news
? BULLISHIMPACT 7/10 8-K filed Feb 25, 2026 at 06:05 ET
LivaNova reported strong full-year 2025 results with double-digit revenue growth and improved margins, driven by both Cardiopulmonary and Neuromodulation segments. Despite a GAAP loss due to a $365.6 million environmental liability, adjusted earnings grew 15.4%. The company issued 2026 guidance for 6-7% revenue growth and $4.15-$4.25 adjusted EPS, supported by increased Medicare reimbursement and FDA approval for a new digital health platform.
- Full-year 2025 revenue grew 10.7% to $1.39 billion, with Cardiopulmonary up 14.9% and Neuromodulation up 7.0%
- Full-year adjusted EPS was $3.90, up 15.4% from $3.38 in 2024
- GAAP loss of $4.45 per share due to $365.6 million SNIA environmental liability expense
- 2026 guidance: 6-7% constant-currency revenue growth and $4.15-$4.25 adjusted EPS
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access